1. Evers M, Ghatak A, Suresh B. McKinsey & Company: a vision for medical affairs in 2025. 2019. https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/a-vision-for-medical-affairs-in-2025. Accessed 1 Mar 2021.
2. Paardekooper C. Medical affairs in transition, towards a fully integrated model. Vintura. 2019. https://www.vintura.com/en/life-science-consulting/publications/whitepaper-medical-affairs-in-transition-towards-a-fully-integrated-model/. Accessed 1 Mar 2021.
3. Mckinsey and Company. COVID-19 implications for life sciences R&D: recovery and the next normal. 2021. https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/covid-19-implications-for-life-sciences-r-and-d-recovery-and-the-next-normal#. Accessed 1 Mar 2021.
4. Rajadhyaksha VD. Medical affairs post-COVID 19: are we ready to take the baton? Perspect Clin Res. 2020;11:124–7 (PMID: 33033702; PMCID: PMC7513787).
5. van Tongeren T. The state of customer experience in the pharmaceutical industry, 2018: HCP interactions. April 2019. 2019. https://dtconsulting.com/the-state-of-customer-experience-in-the-pharmaceutical-industry-2018-hcp-interactions. Accessed 1 Mar 2021.